Italia markets close in 3 hours 7 minutes

Medigene AG (0QGJ.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
1,7400+0,0400 (+2,35%)
Al 10:08AM BST. Mercato aperto.
Schermo intero
Chiusura precedente1,7000
Aperto0,0000
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno0,0000 - 0,0000
Intervallo di 52 settimane
Volume588
Media Volume90
Capitalizzazione427.293
Beta (5 anni mensile)0,94
Rapporto PE (ttm)N/D
EPS (ttm)-0,4060
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein

    Planegg/Martinsried, September 27, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent (EP3 433 269) by the European Patent Office protecting its PD1-41BB costimulatory switch protein (CSP) technology. Medigene’s PD1-41BB CSP was developed by its partner Helmholtz Munich and is exclusively licensed

  • GlobeNewswire

    Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library

    Planegg/Martinsried, September 18, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that it has selected its lead candidate for MDG2011, a T cell receptor engineered T cell (TCR-T) therapy targeting KRAS (Kirsten rat sarcoma viral oncogene homologue) G12V with HLA-A*11 and being developed in combination with the Company’s PD1-41BB costim

  • GlobeNewswire

    Medigene AG to present at the Baader Investment Conference 2023

    Planegg/Martinsried, September 11, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the Baader Investment Conference 2023 in Munich to be held from September 18-21, 2023. Corporate presentation - Baader Investment Conference 2023 https://www.baaderinvestmentconference.com/Date and time: Monday, September 18, 2023, 2:10 pm – 2:50